RGNX
REGENXBIO Inc.NASDAQHealthcare$8.53-1.16%ClosedMarket Cap: $440.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
4.43
P/S
2.66
EV/EBITDA
-4.67
DCF Value
$-25.25
FCF Yield
-27.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
52.9%
Operating Margin
-94.6%
Net Margin
-113.8%
ROE
-103.1%
ROA
-42.8%
ROIC
-42.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $30.3M | 80.5% | $-57.6M | $-67.1M | $-1.30 | — |
| FY 2025 | $170.4M | 88.1% | $-161.2M | $-193.9M | $-3.76 | — |
| Q3 2025 | $29.7M | -107.9% | $-52.4M | $-61.9M | $-1.20 | — |
| Q2 2025 | $21.4M | 57.3% | $-63.3M | $-70.9M | $-1.38 | — |
| Q1 2025 | $89.0M | 96.1% | $12.1M | $6.1M | $0.12 | — |
| Q4 2024 | $21.2M | 70.2% | $-51.4M | $-51.2M | $-1.01 | — |
| FY 2024 | $83.3M | 59.7% | $-233.3M | $-227.1M | $-4.59 | — |
| Q3 2024 | $24.2M | 48.8% | $-62.1M | $-59.6M | $-1.17 | — |
| Q2 2024 | $22.3M | 34.4% | $-56.0M | $-53.0M | $-1.05 | — |
| Q1 2024 | $15.6M | 45.8% | $-61.8M | $-63.3M | $-1.38 | — |
| Q4 2023 | $22.2M | 29.9% | $-63.9M | $-62.9M | $-1.43 | — |
| FY 2023 | $90.2M | 58.8% | $-268.1M | $-263.5M | $-6.02 | — |